A DC vaccine pulsed with HER2/neu peptides yielded modest results in a small phase I trial [85], and a phase II randomized study investigating autologous tumor lysate-pulsed DC & CIK cells in the adjuvant setting in stage I–III gastric cancer is currently recruiting (NCT02215837). Here, ERBB2 is linked to gastric cancer.